Agilent Technologies, Inc. (NYSE:A) Receives $139.77 Consensus PT from Analysts

Agilent Technologies, Inc. (NYSE:A) has been given an average rating of “Moderate Buy” by the thirteen analysts that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $139.77.

Several equities analysts have issued reports on A shares. Leerink Partners boosted their target price on Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 30th. UBS Group decreased their price target on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research note on Thursday, May 29th. Evercore ISI increased their price objective on Agilent Technologies from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 8th. Jefferies Financial Group reduced their target price on Agilent Technologies from $135.00 to $116.00 and set a “hold” rating for the company in a report on Monday, April 21st. Finally, Robert W. Baird lowered their price target on shares of Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating on the stock in a research note on Thursday, May 22nd.

Agilent Technologies Trading Down 1.4%

A opened at $118.15 on Monday. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $153.84. The business’s 50 day moving average is $116.88 and its two-hundred day moving average is $121.18. The firm has a market cap of $33.56 billion, a price-to-earnings ratio of 29.17, a price-to-earnings-growth ratio of 3.64 and a beta of 1.23.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. During the same period last year, the firm posted $1.22 EPS. Agilent Technologies’s revenue for the quarter was up 6.0% on a year-over-year basis. On average, research analysts predict that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 23rd. Investors of record on Tuesday, July 1st were issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date was Tuesday, July 1st. Agilent Technologies’s payout ratio is currently 24.44%.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the firm’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. KPP Advisory Services LLC raised its stake in shares of Agilent Technologies by 11.5% during the second quarter. KPP Advisory Services LLC now owns 3,741 shares of the medical research company’s stock valued at $442,000 after purchasing an additional 385 shares during the period. OLD Point Trust & Financial Services N A increased its stake in Agilent Technologies by 4.6% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 7,304 shares of the medical research company’s stock worth $862,000 after buying an additional 323 shares during the period. Rehmann Capital Advisory Group purchased a new stake in Agilent Technologies during the 2nd quarter worth $212,000. Parcion Private Wealth LLC acquired a new position in Agilent Technologies in the 2nd quarter worth $291,000. Finally, Pacific Heights Asset Management LLC boosted its position in Agilent Technologies by 56.9% in the 2nd quarter. Pacific Heights Asset Management LLC now owns 102,000 shares of the medical research company’s stock valued at $12,037,000 after buying an additional 37,000 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.